meRfi®-GM
Metronidazole & Bacterial vaginosis
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The standard first-line therapy with metronidazole (MTZ) is successful in some cases of bacterial vaginosis (BV), but over 50% of patients experience a recurrence within a year.
Possibly, the reason for frequent recurrence could be the shift of the FGT microbiome towards Lactobacillus iners dominance instead of a Lactobacillus crispatus dominance due to Metronidazole
Mitche…
References (Sources)
- Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis
- High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence
- Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure
- Impact of standard bacterial vaginosis treatment on the genital microbiota, immune milieu, and ex vivo human immunodeficiency virus susceptibility
- Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
- Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis
- Treatment of male sexual partners of women with bacterial vaginosis: A randomized, double-blind, placebo-controlled trial